Nightly THC-CBD gummy will be tested for sleep disturbance in palliative cancer care
Sleep disturbance affects a large share of people with cancer, and in palliative care the problem often travels with pain, anxiety, fatigue, and other symptoms that erode day-to-day function. A new protocol from Ohio State University sets out to test whether a low-dose cannabis gummy can be used safely and feasibly to address that burden in adults newly entering palliative care with at least moderate sleep disturbance.
The study is a five-week, pilot, randomized, parallel-arm trial designed around a pragmatic clinical question: can a nightly oral cannabis product be delivered in a real-world oncology setting, and does it show enough signal on sleep and related symptoms to justify a larger trial? Investigators plan to enroll 50 patients from the Ohio State University Comprehensive Cancer Center and randomize participants by sex and race strata to usual care or to a gummy containing 5 mg THC and 5 mg CBD taken one hour before bedtime for 30 days.
A single low-dose intervention will not answer everything, but it is aimed squarely at the symptom cluster that matters most to patients trying to sleep through cancer treatment and advanced illness.
Why sleep remains such a difficult target in cancer care
The protocol is built on a symptom reality that oncology clinicians know well. Sleep disturbance is common in cancer, and it rarely appears alone. Pain, treatment effects, emotional distress, and disease-related changes often overlap, creating a cycle in which poor sleep worsens fatigue and distress, and those same symptoms make sleep harder to recover the next night. In palliative care, that cycle can be especially entrenched because symptom burden is often high and multiple medications may already be in play.
Cannabis has become a frequent self-directed sleep aid among adults with cancer, yet the clinical evidence base remains thin. The paper’s background section points to a sharp mismatch between patient interest and the amount of controlled data available in cancer populations. Most prior work has involved pharmaceutical cannabis preparations rather than the kinds of products patients actually use, and many studies have evaluated sleep only as a secondary endpoint in people who did not enter the study with a primary sleep complaint.
The protocol leans on a biologically plausible mechanism. THC and CBD may promote sleep through sedation, reduced sleep latency, and suppression of cortisol release. In practice, those mechanisms could matter for patients whose insomnia is driven less by one isolated factor than by a layered mix of pain, stress, medication effects, and circadian disruption. Whether that translates into meaningful benefit, however, remains an empirical question the trial is built to ask directly.
Trial design centers on feasibility before efficacy
The study is not set up as a definitive efficacy trial. Its first job is to determine whether the intervention can be delivered, tolerated, and followed in a busy palliative oncology clinic. Eligible participants must be new to the OSUCCC palliative care clinic, report at least moderate sleep disturbance, and have not used cannabis in the past six months. Because this is a pilot, the design is unblinded and unbalanced.
Participants assigned to the active arm will receive the nightly gummy for 30 days, while those assigned to usual care will continue standard management. Baseline assessment is followed by repeated symptom monitoring, with sleep, health-related quality of life, and related symptoms captured through self-report questionnaires, ecological momentary assessments, and actigraphy. Investigators will also monitor adverse events throughout the study, an essential step in any protocol involving a psychoactive product in a medically fragile population.
The monitoring schedule is unusually detailed for a pilot, and that is where much of the protocol’s value lies. Web-based ecological momentary assessments will be sent three days per week by text message or email, allowing investigators to track adverse events, blood pressure via a take-home monitor, and crossover events such as use of sleep aids or additional cannabis. The use of actigraphy adds an objective layer to the study, helping separate perceived sleep change from movement-based estimates of sleep duration and continuity.
Safety and adherence will determine whether the intervention is workable
This is where the trial becomes clinically consequential. If patients cannot or will not take the gummy regularly, or if adverse effects interfere with sleep or daily functioning, the study will have answered an important question even without a positive efficacy signal. Pilot work in palliative care often rises or falls on tolerability, because symptom relief is only useful if the intervention fits into the routines and vulnerabilities of people already carrying a heavy treatment burden.
The study also addresses a regulatory and operational hurdle that often sits behind cannabis research without making it part of the headline: access through a structured investigational pathway. The protocol notes the use of an investigational drug service and an investigational new drug framework, reflecting the administrative complexity required to study a cannabis product inside a cancer center. For patients, that structure matters because it standardizes dosing and safety monitoring rather than relying on ad hoc use.
What the five-week readout can and cannot answer
No datasets were generated yet, and the paper is explicit that the project is still a protocol rather than a results report. That limits what can be said about benefit. It also makes the study more honest about its scope. The investigators are not claiming that cannabis works for cancer-related insomnia; they are testing whether a defined oral product can be studied safely and whether early signals on sleep and symptom burden are strong enough to justify a larger multisite trial.
A positive pilot would not settle clinical practice. It would do something narrower and more useful at this stage: define feasibility in a population that frequently turns to cannabis anyway, while generating preliminary data on sleep disturbance, symptom burden, and quality of life. A negative pilot would be informative as well, especially if adherence is poor or adverse events become common enough to blunt any practical value of the intervention.
The study’s main limitation is embedded in its design. Fifty patients, a single center, short follow-up, and an unblinded randomized structure can only provide early signals, not definitive efficacy. Yet in palliative oncology, those early signals are often the difference between a promising hypothesis and a trial that never gets built. The next step depends on whether the gummy can improve sleep without creating new burdens in a population already coping with cancer, symptom complexity, and limited reserve.